IRulya Therapeutics (formerly Quince Therapeutics) reported Q3 2026 financial results and provided a corporate update following its recent rebranding and leadership appointments. The company ended the quarter with $105.2 million in cash, which is expected to fund operations through 2028, supporting Phase 2 clinical readouts for its lead candidate LAM-001 in pulmonary diseases.
Term
Q3 2026
“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases. By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.
IRulya Therapeutics Inc. (formerly Quince Therapeutics) has posted its updated Corporate Presentation for October 2026 to its website and filed it as an exhibit. The presentation provides a strategic overview of the company's product candidates, specifically LAM-001, and outlines planned clinical milestones and market opportunities in pulmonary hypertension and related lung diseases.
Quince Therapeutics (renaming to IRulya Therapeutics) announced the resignation of CEO Dirk Thye and COO Brendan Hannah, effective October 8, 2026. Brigette Roberts, M.D., has been appointed as the new Chief Executive Officer, bringing a base salary of $600,000 and a 50% target bonus. The leadership transition coincides with a corporate rebrand and a strategic focus on the clinical development of LAM-001 for pulmonary diseases.
Quince Therapeutics stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP) at a special meeting. The 2026 Plan has an initial reserve of 821,872 shares plus potential carryover from prior plans, while the 2026 ESPP has an initial reserve of 142,045 shares, both featuring annual evergreen increase provisions through 2036.
Quince Therapeutics announced the conditional resignations of three board directors (June Bray, David Lamond, and Christopher Senner) and the appointment of four new directors (Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise). These changes are contingent upon shareholder approval of several proposals at a Special Meeting on October 6, 2026, including a conversion proposal that may result in a change of control. The resignations were not due to any disagreements with the company's operations or policies.